Last reviewed · How we verify
Otitis externa caused by Pseudomonas aeruginosa — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Levaquin | levofloxacin | Generic (originally Daiichi Sankyo/J&J) | Fluoroquinolone Antibacterial [EPC] | CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 | 1996-12-20 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Daiichi Sankyo/J&J) · 1 drug in Otitis externa caused by Pseudomonas aeruginosa
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Otitis externa caused by Pseudomonas aeruginosa:
- Otitis externa caused by Pseudomonas aeruginosa treatment updates — RSS
- Otitis externa caused by Pseudomonas aeruginosa treatment updates — Atom
- Otitis externa caused by Pseudomonas aeruginosa treatment updates — JSON
Cite this brief
Drug Landscape (2026). Otitis externa caused by Pseudomonas aeruginosa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/otitis-externa-caused-by-pseudomonas-aeruginosa. Accessed 2026-06-10.
Related
- Otitis externa caused by Pseudomonas aeruginosa full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing